Sage Therapeutics (NASDAQ:SAGE) Earns “Neutral” Rating from HC Wainwright

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $14.00. HC Wainwright’s price target indicates a potential upside of 67.13% from the stock’s current price.

Several other equities research analysts have also issued reports on the company. Piper Sandler dropped their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Scotiabank dropped their price target on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research report on Monday, December 16th. Finally, Oppenheimer dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and an average price target of $9.65.

Sage Therapeutics Trading Up 0.3 %

Sage Therapeutics stock opened at $7.18 on Wednesday. The stock has a market cap of $439.20 million, a P/E ratio of -1.29 and a beta of 0.94. The stock has a 50 day moving average of $6.34 and a 200-day moving average of $6.93. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. As a group, equities analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SAGE. Picton Mahoney Asset Management increased its holdings in shares of Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 3,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in Sage Therapeutics during the fourth quarter valued at about $49,000. Ieq Capital LLC bought a new position in Sage Therapeutics during the fourth quarter valued at about $57,000. US Bancorp DE boosted its stake in Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 2,268 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 2,446 shares in the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.